200 related articles for article (PubMed ID: 25888010)
1. Potential role of surgical resection for pancreatic cancer in the very elderly.
Kinoshita S; Sho M; Yanagimoto H; Satoi S; Akahori T; Nagai M; Nishiwada S; Yamamoto T; Hirooka S; Yamaki S; Ikeda N; Kwon AH; Nakajima Y
Pancreatology; 2015; 15(3):240-6. PubMed ID: 25888010
[TBL] [Abstract][Full Text] [Related]
2. Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.
Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Ohge H; Sueda T
J Gastrointest Surg; 2009 Jan; 13(1):85-92. PubMed ID: 18704593
[TBL] [Abstract][Full Text] [Related]
3. Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakagawa N; Sasaki H; Sueda T
Cancer Chemother Pharmacol; 2013 Feb; 71(2):419-29. PubMed ID: 23178955
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
[TBL] [Abstract][Full Text] [Related]
5. S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Kozuki A; Tokumaru T; Iiyama T; Kosaki T; Kobayashi M; Hanazaki K
World J Surg; 2014 Nov; 38(11):2986-93. PubMed ID: 25104544
[TBL] [Abstract][Full Text] [Related]
6. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
[TBL] [Abstract][Full Text] [Related]
7. Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer.
Morita Y; Sakaguchi T; Kitajima R; Furuhashi S; Kiuchi R; Takeda M; Hiraide T; Shibasaki Y; Kikuchi H; Konno H; Takeuchi H
BMC Cancer; 2019 May; 19(1):416. PubMed ID: 31046709
[TBL] [Abstract][Full Text] [Related]
8. Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study.
Todaka A; Nara S; Motoi F; Morinaga S; Toshiyama R; Higuchi R; Konishi M; Shirakawa H; Tsumura H; Okuyama H; Nagano H; Shioji K; Sugimachi K; Asagi A; Mizuno N; Furuse J
Anticancer Res; 2022 Feb; 42(2):893-902. PubMed ID: 35093887
[TBL] [Abstract][Full Text] [Related]
9. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Motoi F; Satoi S; Honda G; Wada K; Shinchi H; Matsumoto I; Sho M; Tsuchida A; Unno M;
J Gastroenterol; 2019 Feb; 54(2):194-203. PubMed ID: 30182219
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakagawa N; Ohge H; Sueda T
Am J Surg; 2008 Jun; 195(6):757-62. PubMed ID: 18367131
[TBL] [Abstract][Full Text] [Related]
11. [A Case of Gemcitabine Refractory Lung Metastasis after Distal Pancreatectomy for Pancreatic Cancer, Effectively Treated with S -1 as Second Line Chemotherapy].
Omori K; Wakabayashi K; Suematsu Y; Suda H; Hiratsuka M; Takahashi M; Saito H; Ishibashi Y; Morita A; Ito Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1582-4. PubMed ID: 26805103
[TBL] [Abstract][Full Text] [Related]
12. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
[TBL] [Abstract][Full Text] [Related]
13. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Nakagawa N; Sueda T
J Surg Oncol; 2012 Aug; 106(2):174-80. PubMed ID: 22331838
[TBL] [Abstract][Full Text] [Related]
15. Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
Shimoda M; Kubota K; Shimizu T; Katoh M
Br J Surg; 2015 Jun; 102(7):746-54. PubMed ID: 25833230
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Ohge H; Sueda T
J Surg Oncol; 2011 Aug; 104(2):146-54. PubMed ID: 21538357
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.
Suzuki T; Mori S; Shimizu T; Tago K; Harada N; Park KH; Sakuraoka Y; Shiraki T; Iso Y; Aoki T; Kubota K
In Vivo; 2019; 33(6):2027-2035. PubMed ID: 31662534
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Pancreas; 2021 May-Jun 01; 50(5):744-750. PubMed ID: 34016892
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma in Elderly Patients: Special Reference to Postoperative Adjuvant Chemotherapy.
Watanabe Y; Shinkawa T; Endo S; Abe Y; Nishihara K; Nakano T
World J Surg; 2018 Aug; 42(8):2617-2626. PubMed ID: 29383429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]